Rise of the natural red pigment 'prodigiosin' as an immunomodulator in cancer

Cancer Cell Int. 2022 Dec 28;22(1):419. doi: 10.1186/s12935-022-02815-4.

Abstract

Cancer is a heterogeneous disease with multifaceted drug resistance mechanisms (e.g., tumour microenvironment [TME], tumour heterogeneity, and immune evasion). Natural products are interesting repository of bioactive molecules, especially those with anticancer activities. Prodigiosin, a red pigment produced by Serratia marcescens, possesses inherent anticancer characteristics, showing interesting antitumour activities in different cancers (e.g., breast, gastric) with low or without harmful effects on normal cells. The present review discusses the potential role of prodigiosin in modulating and reprogramming the metabolism of the various immune cells in the TME, such as T and B lymphocytes, tumour-associated macrophages (TAMs), natural killer (NK) cells, and tumour-associated dendritic cells (TADCs), and myeloid-derived suppressor cells (MDSCs) which in turn might introduce as an immunomodulator in cancer therapy.

Keywords: B Cells; MDSCs; NK Cells; Prodigiosin; T Cells; TADCs; TAMs; TME.

Publication types

  • Review